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Glucagon levels are increasingly being included as endpoints in clinical study design and more than 400 current diabetes-related
clinical trials have glucagon as an outcome measure. The reliability of immune-based technologies used to measure endogenous
glucagon concentrations is, therefore, important. We studied the ability of immunoassays based on four different technologies
to detect changes in levels of glucagon under conditions where glucagon levels are strongly suppressed. To our surprise, the
most advanced technological methods, employing electrochemiluminescence or homogeneous time resolved fluorescence (HTRF)
detection, were not capable of detecting the suppression induced by a glucose clamp (6mmol/L) with or without atropine in five
healthy male participants, whereas a radioimmunoassay and a spectrophotometry-based ELISA were. In summary, measurement
of glucagon is challenging even when state-of-the-art immune-based technologies are used. Clinical researchers using glucagon
as outcome measures may need to reconsider the validity of their chosen glucagon assay. The current study demonstrates that the
most advanced approach is not necessarily the best when measuring a low-abundant peptide such as glucagon in humans.
1. Introduction
Glucagon, a 29-amino-acid peptide secreted from the pan-
creatic alpha cells in response to hypoglycemia [1], is derived
from the proglucagon molecule, which is also expressed
in the intestine and brain [2]. Glucagon has stimulatory
effect on hepatic glucose production, and dysregulation of
its secretion may contribute to the development of dia-
betes [3–6]. Glucagon measurements are, therefore, often an
important study outcome; according to clinicaltrials.gov, it is
included as an endpoint in more than 400 clinical studies.
However, measurement of glucagon is a delicate matter and
the validity of the data relies on sufficient specificity and
sensitivity of the assay. Differential tissue-specific processing
of proglucagon results in molecular heterogeneity, meaning
that assay specificity with respect to the different molecular
forms is important. Thus, in addition to glucagon itself,
proglucagon gives rise to several peptides containing the
glucagon sequence, including oxyntomodulin, glicentin, and
proglucagon 1–61, as well as molecules with some sequence
homology to glucagon, including glucagon-like peptide-1
(GLP-1) and glucagon-like peptide-2 (GLP-2) and major
proglucagon fragment [7]. Furthermore, each of thesemolec-
ular forms may occur in extended or truncated forms, which
may or may not be biologically active [2]. The immediate
specificity problem is therefore of considerable magnitude.
Sensitivity is equally important, since glucagon occurs in low
picomolar concentrations in the circulation. Its concentration
rises in response to hypoglycemia and falls in response to
rising glucose (e.g., after carbohydrate meals), with the rate
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of as well as the absolute magnitude of the decrease being of
considerable importance for the resulting glucose tolerance.
The ability of assays to register these decreases from already
low levels is, therefore, critical [8].
In the current study, we investigated assays based on
four widely applied immune-based technologies: a radioim-
munoassay (RIA), a spectrophotometric enzyme-linked
immunoassay (ELISA), and ELISAs based on electrochemi-
luminescence (ECL), and homogeneous time-resolved fluo-
rescence (HTRF) detection. We hypothesized that the assay
type might influence measured glucagon concentrations. To
address this, we analyzed glucagon levels during a glucose
clamp with or without atropine (atropine blocks cholinergic
signaling through the muscarinic receptors and leads to fur-
ther suppression of glucagon secretion) in five healthy male
participants using these four different approaches; previous
measurements indicated that the clamp + atropine protocol
resulted in pronounced suppression of glucagon levels [9].
2. Methods
2.1. Participants, Procedures, and Samples. Samples were
derived froma previously published study by Plamboeck et al.
[9].The study was conducted in accordance with theHelsinki
Declaration II and was approved by the Scientific-Ethical
Committee of the Capital Region of Denmark (registration
number: H-2-2011-062) and by the Danish Data Protection
Agency (journal number: 2011-41-6381) and registered at clin-
icaltrials.gov (ID: NCT01534442). Oral and written informed
consent was obtained from all participants. Glucose clamps
(6mmol/L) were performed in five healthy male participants
(age: 25 ± 1 years, body mass index: 24 ± 0.5 kg/m2, and
HbA
1c: 5.1±1%)with orwithout blocking efferentmuscarinic
activity by infusion of atropine (1mg bolus + an 80 ng/kg/min
infusion). Samples were collected and stored using optimal
conditions for glucagon analysis as described previously [8].
2.2. Measurement of Glucagon. We used four immune-based
assays for measurement of glucagon: (A) an in-house C-
terminal RIA (codename 4305) [6, 8, 10]; (B) Mercodia
sandwich ELISA (spectrophotometry) (cat# 10-1271-01, Upp-
sala, Sweden); (C) sandwich ELISA from MSD (chemilu-
minescence) (cat# K151HCC-1, MD 21201, USA); and (D)
sandwich ELISA from Cis-Bio (homogeneous time-resolved
fluorescence) (cat# 62GLCPEK, Codolet, France). Assays
were carried out as per protocol according to the manufac-
turers’ instructions. Samples were kept cold (ice-bath) at all
times, and all samples were measured simultaneously in a
single run to eliminate interassay variance.
2.3. Statistics. To analyze changes in glucagon levels over
time, a one-way ANOVA for repeated measurements fol-
lowed by a Bonferroni post hoc analysis was performed for
each of the four assays. To compare the ability of the assays to
detect changes in glucagon levels, we created a generalized
regression model (ANCOVA) with glucagon as dependent
variable and time (minutes) and method (assay) as indepen-
dent variables. Net area under the curve (delta changes from
time zero to 160 minutes relative to the individual baselines)
(nAUC) was calculated using the trapezoidal rule and differ-
ences were tested using a two-sided test. A power calculation
was made based on the following assumptions: normality
of data distribution, homoscedasticity, one-sample 𝑡-test,
quantification limits and coefficient of variations provided
by the manufacturers, an alpha value of 0.05, and a sample
size of five. The calculation showed that the power to detect
significant changes (of 5%) in glucagon levels ranged from
79% to 84% across the four assays. 𝑃 < 0.05 was considered
significant. Calculations were made using GraphPad Prism
version 6.04 for Windows, GraphPad Software, La Jolla,
California, USA, http://www.graphpad.com/, and STAT14,
Boston, MA, USA. For illustrations we used the Adobe CS6
software suite (California, USA).
3. Results
Therecoveries of synthetic glucagon in pooled human plasma
(𝑁 = 4) were 95 ± 11% (assay A), 104 ± 5% (assay B),
75 ± 15% (assay C), and 67 ± 21% (assay D). Glucagon
levels dropped significantly compared to baseline (time =
0min) in both saline and atropine treated groups (𝑃 < 0.01)
when samples were measured using assay A (Figure 1(a))
and assay B (Figure 1(b)) but not with assay C (Figure 1(c),
𝑃 = 0.31) and assay D (Figure 1(d), 𝑃 = 0.24). Assay A
was significantly different (𝑃 < 0.05) from assays C and
D but not assay B (𝑃 = 0.43). Assay B was significantly
different from assays C and D (𝑃 < 0.05) whereas there
were no differences between assays C and D (𝑃 = 0.27).
nAUCs during infusion of saline and atropine, respectively,
for assay A and assay B were significantly different (𝑃 <
0.001), indicating further suppression of glucagon secretion
with atropine addition. For assays C and D, nAUCs were
significantly different between atropine (𝑃 < 0.01) and saline,
indicating that atropine weakly suppressed glucagon levels
compared to the clamp alone, where nAUCs did not show
significance compared to baseline (zero) by one-side 𝑡-test
(𝑃 = 0.11 and 𝑃 = 0.17).
4. Discussion
Immune-based detection methods utilize the extreme bind-
ing energy of antibodies which may have equilibrium con-
stants reaching values of 1012 L/mol, providing thesemethods
with a potential to measure very low concentrations. How-
ever, the use of antibodies relies on their specificity and the
antigen-antibody reaction may also may be sensitive to the
so-called matrix effects, that is, interference from compo-
nents in plasma including a variety of high-abundant plasma
molecules or proteins (e.g., albumin and immunoglobulins),
leading to unspecific interference in antibody-antigen inter-
action [11].
Assay D uses the homogeneous time-resolved fluores-
cence technology which combines fluorescence resonance
energy transfer technology (FRET) with time-resolved mea-
surement (TR) [12].HRTF ismainly used in (in vitro) primary
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Figure 1: Plasma glucagon levels of five healthy participants during a 6mmol/L glucose clamp with simultaneous infusion of either saline
(black) or atropine (red). (a) depicts assay A, a radioimmunoassay; (b) depicts assay B, a spectrophotometrically based ELISA; (c) depicts
assay C, a chemiluminescence based ELISA; and (d) depicts assay D, a homogeneous time-resolved fluorescence based ELISA. Net area under
the curve (nAUC) is depicted separately at upper right quadrant on (a), (b), (c), and (d). ∗ represents a significant two-sided 𝑡-test comparing
saline nAUC to atropine nAUC. Data illustrated as mean ± standard deviation.
and secondary screening phases of drug development. How-
ever, its usefulness in highly sensitive immunoassays required
for detection of 1 pmol/L differences in glucagon levels may
be questioned. In contrast, assay C applies an electrochemilu-
minescence approach: when excited by electrical stimulation,
labeled molecules emit light, which then is detected by
cameras. The most generic ELISA used in our study is assay
B, involving spectrophotometry detection; a chromogenic
substrate is added to sample wells, which is then cleaved
by an enzyme, for example, horseradish peroxidase, coupled
to the detection antibody. Assay A is a radioimmunoassay
utilizing competition between radioactively labeled antigen
and unlabeled antigen (peptide standard or sample with
unknown concentration) for binding to a limited number
of specific antibody binding sites. Although it is the most
simple, with regard to technology, the data clearly shows that
assays A and B perform significantly better than assays C
and D. However, a requirement for such a performance is
the application of antibodies with sufficient binding energy
(and specificity), which is often the crucial step in assay
development.
In this study, we highlight the crucial importance of
choosing the “right” immune-based method when analyzing
endogenous glucagon. We have exemplified the challenge
by demonstrating that changes in measured glucagon levels
depend on the assay used (Figure 1); where assays A and
B clearly register the attenuation of glucagon levels during
a glucose clamp, assays C and D did not. The basal levels
measured were comparable, around 15 pmol/L (although
assayC showed slightly higher levels, around 20 pmol/L).This
may reflect a specificity problem in assay C; for example, this
assay could be cross-reacting with glucagon-like molecules
(oxyntomodulin, glicentin, or glucagon-like peptide-1 [7,
11]) although not stated by the manufacturers. Otherwise,
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the difference between the assays, although not formally
tested here, most likely reflects differences in sensitivity and
therefore ability to detect dynamic changes in the very low
picomolar range. In a previous study [6], a sensitivity analysis
was carried out for assays A and B (where assay A was
more sensitive), and, in another study of other commercially
available assays [7], sensitivity was clearly insufficient to allow
analysis in this concentration range. In addition, we recently
demonstrated that measured glucagon levels in subjects with
renal dysfunction may erroneously appear elevated, probably
due to cross-reactions with N-terminal elongated inactive
isoforms of the glucagonmolecule (1–61) when analyzed with
conventional single antibodyC-terminal radioimmunoassays
[6]. Importantly for interpretation of clinical studies, the
potential instability of glucagon during inappropriate sample
preparation and storage, such as multiple freeze-thaw cycles
or storing plasma samples at room temperature formore than
1 hour, should also be considered [8].
Novel mass-spectrometry based detection (e.g., selected
reaction monitoring (SRM)) of low-abundant peptides as
glucagon [13] may in the future facilitate validation of
immune-based detection methods. Unfortunately, current
mass-spectrometry based methods still depend on 2D-gel
extraction techniques or bead-coupled antibodies [14] both of
which have questionable recoveries and specificity. However,
in the future mass-spectrometry based detection methods
may involve label-free (be it chemical or antibody based)
purification steps as recently demonstrated [15] and may
therefore provide accurate validation.
In conclusion, levels of glucagon are increasingly being
used as outcome measures in clinical trials and the reliability
of the glucagon assays employed is therefore critical for
appropriate interpretation of the data.
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